One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis.
| Published in: | Targeted Oncology pp. 1 - 12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Sep2026
|
| Online Access: | View this record in EBSCOhost |